Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.40 |
| ▸ | CDC7 | O00311 | 2/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 3/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12344590 | 0.74 | PIK3C3 (0.37) | NAMPTPIK3C3FGFR1BRAFMAPK1 | |
| SCHEMBL29930822 | 0.73 | TRPA1 (0.46) | CDC7PIK3C3FGFR1BRAFMAPK1 | |
| SCHEMBL29705478 | 0.73 | MAPT (0.50) | PIK3C3FGFR1BRAFMAPK1HTT | |
| SCHEMBL29705375 | 0.73 | FGFR1 (0.40) | NAMPTPIK3C3FGFR1FGFR2BRAF | |
| SCHEMBL15243458 | 0.73 | NOS1 (0.50) | PIK3C3FGFR1BRAFMAPK1HTT | |
| SCHEMBL3429629 | 0.73 | PIK3C3 (0.36) | PIK3C3FGFR1BRAFMAPK1HTT | |
| SCHEMBL1496196 | 0.73 | MAPT (0.50) | PIK3C3FGFR1BRAFMAPK1HTT | |
| SCHEMBL10329 | 0.73 | DYRK1A (0.50) | PIK3C3FGFR1MAPK1HTTMKNK1 | |
| SCHEMBL20674185 | 0.73 | FGFR1 (0.40) | NAMPTPIK3C3FGFR1FGFR2BRAF | |
| SCHEMBL11982852 | 0.73 | PIK3C3 (0.36) | NAMPTPIK3C3FGFR1BRAFMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113354638-A | Preparation method of 5-fluoro-3-iodo-1H-pyrazolo [3,4-b ] pyridine | 天津敬康生物科技有限公司 | 2021-09-07 | — | — | CN | claimed |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| WO-2025264700-A1 | GIP RECEPTOR AGONIST COMPOUNDS | ELI LILLY AND COMPANY (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250197399-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-12275720-B2 | Small molecule inhibitors of galectin-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-15 | — | — | US | disclosed |
| WO-2025052129-A1 | PYRIDINE DERIVATIVES WHICH ACT AS INHIBITORS OF MPTP. | NRG THERAPEUTICS LTD (GB) | 2025-03-13 | — | — | WO | disclosed |
| EP-4499626-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Nico Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119233972-A | Compounds, compositions, and methods | 尼科治疗有限公司 | 2024-12-31 | — | — | CN | disclosed |
| EP-2896617-B1 | METHOD FOR PRODUCING SUBSTITUTED (Z)-ALPHA-FLUORO-BETA-AMINO-ACRYLALDEHYDES | ADVERIO PHARMA GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-20160009671-A1 | PROCESS FOR PREPARING SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES | ADVERIO PHARMA GMBH (DE) | 2016-01-14 | — | — | US | disclosed |
| US-9150573-B2 | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines | ADVERIO PHARMA GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| EP-2896617-A1 | Method for producing substituted 5-fluoro-1h-pyrazolopyridines | Adverio Pharma GmbH (DE) | 2015-07-22 | — | — | EP | disclosed |
| US-20140315926-A1 | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines | ADVERIO PHARMA GMBH (DE) | 2014-10-23 | — | — | US | disclosed |
| EP-2782914-A1 | METHOD FOR PRODUCING SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2014-10-01 | — | — | EP | disclosed |
| US-8802847-B2 | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-20130211090-A1 | METHOD FOR THE PRODUCTION OF 5-FLUORO-1H-PYRAZOLO[3,4-B]PYRIDINE-3-CARBONITRILE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130143900-A1 | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-06 | — | — | US | disclosed |
| WO-2013076168-A1 | METHOD FOR PRODUCING SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275720-B2 | Small molecule inhibitors of galectin-3 | LGALS3, LGALS3BP, LGALS1 | NAMPT 849/4885CDC7 3503/4885PIK3C3 2017/4885 |
| US-20130211090-A1 | METHOD FOR THE PRODUCTION OF 5-FLUORO-1H-PYRAZOLO[3,4-B]PYRIDINE-3-CARBONITRILE | CYP4F3, CYP2F1, CYP4B1 | NAMPT 273/4885CDC7 2921/4885PIK3C3 2958/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | NAMPT 4738/4885CDC7 3905/4885PIK3C3 3285/4885 |
| US-20160009671-A1 | PROCESS FOR PREPARING SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES | CYP3A5, CYP4F2, CYP2F1 | NAMPT 1428/4885CDC7 3085/4885PIK3C3 2625/4885 |
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | NAMPT 4430/4885CDC7 3436/4885PIK3C3 3694/4885 |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GCGR | NAMPT 4439/4885CDC7 3110/4885PIK3C3 3524/4885 |
| US-20130143900-A1 | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines | CYP3A5, CYP4F2, CYP2F1 | NAMPT 1428/4885CDC7 3085/4885PIK3C3 2625/4885 |
| US-20140315926-A1 | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines | CYP3A5, CYP4F2, CYP2F1 | NAMPT 1428/4885CDC7 3085/4885PIK3C3 2625/4885 |
| US-20250197399-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NLRP3, NLRP1, NOD1 | NAMPT 294/4885CDC7 2150/4885PIK3C3 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.